Phaseline

Companies › Kyntra Bio

Kyntra Bio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FG-3246
anti-CD46 antibody-drug conjugate
CD46Phase 2Metastatic Castration-Resistant Prostate CancerMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06842498FG-3246Phase 2Metastatic Castration-Resistant Prostate CancerOncologyMar 2028

From the company's SEC filings

Cash and short-term investments of $91m on 2026-06-30; operating cash outflow about $36m a year; runway about 30 months at that burn, to Jan 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

CD46 (1)

Companies with the same targets

–

Companies built like this

Black Diamond Therapeutics CNS Pharmaceuticals Faeth Therapeutics BioLineRx Allarity Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.